Physician profile
Jeffrey Frankel
NPI 1487694154
$393,409.69
in general payments reported to CMS, 2019-2025
36 companies · $51K in 2025
The $51K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $33K · 2021: $34K · 2022: $79K · 2023: $119K · 2024: $51K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $140K · Consulting Fee: $53K · Travel and Lodging: $24K · Food and Beverage: $4,209 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $139,784.29 |
| Consulting Fee | $53,155.00 |
| Travel and Lodging | $23,819.59 |
| Food and Beverage | $4,208.99 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $209,833.42 | 2023-2025 | Orgovyx, Gemtesa |
| Myovant Sciences INC. | $65,356.99 | 2021-2022 | |
| Astellas Pharma US INC | $55,744.64 | 2019-2024 | Xtandi |
| Pfizer INC. | $25,206.78 | 2019-2025 | |
| Tolmar Pharmaceuticals, INC. | $17,406.93 | 2022 | |
| Urovant Sciences INC | $9,574.92 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $3,443.19 | 2020-2023 | Lynparza |
| Myovant Sciences Gmbh | $1,530.57 | 2021 | |
| Janssen Scientific Affairs, LLC | $834.49 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $476.97 | 2019-2025 | Provenge |
| Ferring Pharmaceuticals INC. | $451.03 | 2019-2025 | Adstiladrin |
| Janssen Biotech, INC. | $407.06 | 2019-2021 | |
| Verathon INC. | $400.00 | 2021 | |
| Abbvie INC. | $355.24 | 2019-2021 | |
| Progenics Pharmaceuticals, INC. | $353.66 | 2021-2023 | Pylarify |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $255.05 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $244.42 | 2019-2021 | |
| Boston Scientific Corporation | $192.88 | 2019 | |
| Teleflex LLC | $175.65 | 2021-2022 | |
| Immunitybio, INC. | $162.08 | 2025 | |
| Coloplast Corp | $161.11 | 2019-2020 | |
| Astellas Pharma INC | $140.88 | 2024 | Xtandi |
| Convatec INC. | $118.25 | 2019-2021 | |
| 180 Medical, INC. | $97.26 | 2020-2021 | |
| Myriad Genetic Laboratories, INC. | $94.96 | 2020-2021 | |
| Dentsply Ih INC. | $88.39 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $87.10 | 2021 | |
| Rochester Medical Corporation | $58.15 | 2020-2021 | |
| Astellas Pharma Global Development | $47.49 | 2019-2021 | |
| Axonics, INC. | $35.07 | 2022 | |
| Verity Pharmaceuticals INC. | $33.74 | 2021 | |
| Urogen Pharma, INC. | $24.92 | 2021 | |
| Laborie Medical Technologies Corp. | $16.40 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Frankel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.